NASDAQ:CKPT - Checkpoint Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Checkpoint Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.93 -0.12 (-5.85 %) (As of 02/28/2020 09:50 AM ET) Add Compare Today's Range$1.90Now: $1.93▼$1.9950-Day Range$1.56MA: $1.95▼$2.4352-Week Range$1.12Now: $1.93▼$5.20Volume17,742 shsAverage Volume232,986 shsMarket Capitalization$73.77 millionP/E RatioN/ADividend YieldN/ABeta2.68 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CKPT Previous Symbol CUSIPN/A CIK1651407 Webhttp://www.checkpointtx.com/ Phone781-652-4500Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.51 million Price / Sales21.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book4.60Profitability EPS (Most Recent Fiscal Year)($1.27) Net Income$-36,370,000.00 Net Margins-583.52% Return on Equity-339.99% Return on Assets-158.34%Miscellaneous Employees7 Outstanding Shares38,220,000Market Cap$73.77 million Next Earnings Date3/20/2020 (Estimated) OptionableNot Optionable Receive CKPT News and Ratings via Email Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CKPT Rates by TradingView Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions What is Checkpoint Therapeutics' stock symbol? Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT." How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics Inc (NASDAQ:CKPT) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.02. The company earned $0.28 million during the quarter, compared to the consensus estimate of $0.70 million. Checkpoint Therapeutics had a negative return on equity of 339.99% and a negative net margin of 583.52%. View Checkpoint Therapeutics' Earnings History. When is Checkpoint Therapeutics' next earnings date? Checkpoint Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Checkpoint Therapeutics. What price target have analysts set for CKPT? 2 brokers have issued 1-year price objectives for Checkpoint Therapeutics' shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate Checkpoint Therapeutics' stock price to reach $11.50 in the next year. This suggests a possible upside of 495.8% from the stock's current price. View Analyst Price Targets for Checkpoint Therapeutics. What is the consensus analysts' recommendation for Checkpoint Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Checkpoint Therapeutics. What are Wall Street analysts saying about Checkpoint Therapeutics stock? Here are some recent quotes from research analysts about Checkpoint Therapeutics stock: 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, cosibelimab and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (8/9/2019) 2. According to Zacks Investment Research, "Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. " (3/20/2019) Has Checkpoint Therapeutics been receiving favorable news coverage? Media coverage about CKPT stock has been trending very negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Checkpoint Therapeutics earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Checkpoint Therapeutics. Who are some of Checkpoint Therapeutics' key competitors? Some companies that are related to Checkpoint Therapeutics include Recro Pharma (REPH), Verrica Pharmaceuticals (VRCA), CytomX Therapeutics (CTMX), Dynavax Technologies (DVAX), Concert Pharmaceuticals (CNCE), Evolus (EOLS), Lexicon Pharmaceuticals (LXRX), Albireo Pharma (ALBO), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Stemline Therapeutics (STML), Minerva Neurosciences (NERV), Evofem Biosciences (EVFM), Osmotica Pharmaceuticals (OSMT) and MannKind (MNKD). What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include PTC Therapeutics (PTCT), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO), Avid Bioservices (CDMO), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP) and ADMA Biologics (ADMA). Who are Checkpoint Therapeutics' key executives? Checkpoint Therapeutics' management team includes the folowing people: Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32) Who are Checkpoint Therapeutics' major shareholders? Checkpoint Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.28%), Geode Capital Management LLC (0.76%), Renaissance Technologies LLC (0.31%), Bank of America Corp DE (0.27%), Acadian Asset Management LLC (0.23%) and Bank of New York Mellon Corp (0.12%). View Institutional Ownership Trends for Checkpoint Therapeutics. Which institutional investors are selling Checkpoint Therapeutics stock? CKPT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC and Geode Capital Management LLC. View Insider Buying and Selling for Checkpoint Therapeutics. Which institutional investors are buying Checkpoint Therapeutics stock? CKPT stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Bank of America Corp DE, Acadian Asset Management LLC, Barclays PLC and UBS Group AG. View Insider Buying and Selling for Checkpoint Therapeutics. How do I buy shares of Checkpoint Therapeutics? Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Checkpoint Therapeutics' stock price today? One share of CKPT stock can currently be purchased for approximately $1.93. How big of a company is Checkpoint Therapeutics? Checkpoint Therapeutics has a market capitalization of $73.77 million and generates $3.51 million in revenue each year. The company earns $-36,370,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.View Additional Information About Checkpoint Therapeutics. What is Checkpoint Therapeutics' official website? The official website for Checkpoint Therapeutics is http://www.checkpointtx.com/. How can I contact Checkpoint Therapeutics? Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected] MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 152 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 289MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: Quantitative Easing
